Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-01-18
2005-01-18
Housel, James (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069300, C536S023100, C536S023500, C424S199100, C424S277100, C424S093200, C424S093600
Reexamination Certificate
active
06844188
ABSTRACT:
The present invention provides methods of preventing and/or treating cancers (including tumors). In one preferred embodiment, the invention is practiced to induce regression of an existing cancer or tumor and/or to prevent metastasis and/or to prevent growth of metastatic nodules. In other preferred embodiments, the invention may be used as a prophylaxis to prevent the development of primary cancers through a childhood or adult vaccination program against specific tumor antigens for cancers with high incidences. In an alternate preferred embodiment, the present invention provides methods of establishing an immune response against a universal artificial tumor antigen through a childhood or adult vaccine program, thus providing a long-term immune response that can be utilized at any point to treat any cancer which develops later in life. The present invention also provides cancer and tumor cells stably expressing an artificial antigen, preferably an artificial cell-surface antigen.
REFERENCES:
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5951975 (1999-09-01), Falo, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6468982 (2002-10-01), Weiner et al.
patent: WO95/07994 (1995-03-01), None
patent: WO 9507994 (1995-03-01), None
patent: WO 9532733 (1995-12-01), None
patent: WO 9617072 (1996-06-01), None
patent: WO 9621416 (1996-07-01), None
patent: WO 9724447 (1997-07-01), None
patent: WO 9800163 (1998-01-01), None
patent: WO 9930734 (1999-06-01), None
patent: WO 0039318 (2000-07-01), None
patent: WO 9210578 (2002-06-01), None
Caley et al., Journal of Virology, vol. 71 No 4, pp. 3031-3038 (1997).*
Gardner et al., Journal of Virology, vol. 74 No 24, pp. 11849-11857 (2000).*
Disis et al., Journal of Immunology, vol. 156, pp. 3151-3158 (1996).*
Davis et al., Vaccines 95:387-391, 1995.*
Davis et al., Journal of Virology, 70(6):3781-3787, 1996.*
DeVeerman et al.;Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4+T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity, The Journal of Immunology 162:144-151 (1999).
Dietz et al.;High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells, Blood, 91:2 392-398 (1998).
Galili et al.;Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity, Immunology Today 18:6 281-285 (1997).
Ikonomidis et al.;Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines, Vaccine 15:4 433-440 (1997).
Kawakami et al.; Section 3.1Genes Coding for Tumor Antigens Recognized by T Lymphocytes, Biologic Therapy of Cancer Second Edition, J.B. Lippincott Company, 1995 pp. 53-63.
Pan et al.;A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours, Nature Medicine 1:5 471-477 (1995).
Pan et al.;Regression of Established Tumors in Mice Mediated by the Oral Administration of a Recombinant Listeria monocytogenes Vaccine1, Cancer Research 55:4776-4779 (1995).
Restifo;The new vaccines: building viruses that elicit antitumor immunity, Current Opinion in Immunology, 9:658-663 (1997).
Restifo et al.;Transfectant Influenza A Viruses Are Effective Recombinant Immunogens in the Treatment of Experimental Cancer, Virology 249:89-97 (1998).
Rosenberg;A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens, Immunity 10:281-287 (1999).
Schuler et al.;Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors, J. Exp. Med. 186:8 1183-1187 (1997).
Song et al.;Antigen presentation in retroviral vector-mediated gene transfer in vivo, Proc. Natl. Acad. Sci. USA 94:1943-1948 (1997).
Song et al.;Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity, J. Exp. Med. 186:8 1247-1256 (1997).
Specht et al.;Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases, J. Exp. Med. 186:8 1213-1221 (1997).
Storkus et al.; Section 3.2Tumor Antigens Recognized by Immune Cells, Biologic Therapy of Cancer Second Edition, J.B. Lippincott Company, 1995 pp. 64-77.
Wang et al.;Active Immunotherapy of Cancer with a Nonreplicating Recombinant Fowlpox Virus Encoding a Model Tumor Associated Antigen, The Journal of Immunology 154:4685-4692 (1995).
Wu et al.;Tolerance to a Dominant T Cell Epitope in the Acetylcholine Receptor Molecule Induces Epitope Spread and Suppresses Murine Myasthenia Gravis1, The Journal of Immunology 159:6 3016-3023 (1997).
Pushko et al.;Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes in Vitro and Immunization against Heterologous Pathogens in Vivo, Virology 239:389-401 (1997).
International Search Report, PCT/US99/07704, Date of Mailing: Dec. 15, 1999.
Johnston, “Alphavirus Expression Vectors: Potential Applications for Gene Expression, Vaccines and Gene Therapy,” a list of slides,Presentation to the Scientific Advisory Board of OraVax, Inc. Boston, MA (Mar. 31, 1997).
Johnston Robert E.
MacDonald Gene H.
Martin Brian K.
Ting Jenny P.-Y.
Housel James
Lucas Zachariah
Myers Bigel Sibley & Sajovec P.A.
University of North Carolina at CHapel Hill
LandOfFree
Methods and modified cells for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and modified cells for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and modified cells for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435233